Role of angiogenesis in the progression and treatment of prostate cancer

Cancer Investigation

Volumn 19, Issue 2, 2001, Pages 181-191

  Choy, M ^a   Rafii, S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY MECHANISM; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION;

ANDROGENS; ANGIOGENESIS INHIBITORS; CYTOKINES; DISEASE PROGRESSION; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPHOKINES; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035083598     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-100000152     Document Type: Review

References (113)

1. Angiogenesis
2. Angiogenesis in cancer, vascular, rheumatoid and other disease
3. Manipulating angiogenesis. From basic science to the bedside
4. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
5. Mechanisms of angiogenesis
6. Signaling vascular morphogenesis and maintenance
7. Inhibition of angiogenesis
8. Angiogenesis: The unifying concept in cancer?
9. Inhibitors of angiogenesis in a clinical perspective
10. A new approach to fighting cancer?
11. Halting angiogenesis suppresses carcinoma cell invasion
12. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
13. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
14. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like essels by VEGF withdrawal
15. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
16. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning
17. Angiopoietin-1 induces sprouting angiogenesis in vitro
18. Vascular endothelial growth factor is a secreted angiogenic mitogen
19. Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (flk-1) are expressed during vasculogenesis and vascular differentiation in the quail embryo
20. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF Gene
21. Abnormal blood vessel development and lethality in embryos lacking a single VEGF Allele
22. Vascular endothelial growth factor (VEGF) and its receptors
23. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants
24. Vascular endothelial growth factor B, a novel growth factor for endothelial cells
25. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform
26. Genomic organization of human and mouse genes for vascular endothelial growth factor C
27. Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively
28. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia
29. A comparative study of the expression patterns for Vegf, Vegf-b/Vrf and Vegf-c in the developing and adult mouse
30. VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane
31. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
32. Vascular endothelial growth factors VEGF-B and VEGF-C
33. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia
34. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
35. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7, VEGF), prefrentially utilizes KDR/FIk-1 receptor and carries a potent mitotic activity without heparin-binding domain
36. Vascular endothelial growth factor and its receptors
37. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype
38. Failure of blood-island formation and vasculogenesis in Flk-l-deficient mice
39. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
40. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
41. Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study
42. Tumour angiogenesis in latent prostatic carcinoma
43. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting
44. Expression of multiple angiogenic cytokines in cultured normal human prostate epithelial cells: Predominance of vascular endothelial growth factor
45. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia
46. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells
47. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In ditu and in vitro expression of VEGF by human prostate cancer cells
48. Serum vascular endothelial growth factor is often elevated in disseminated cancer
49. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine Kinases
50. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis
51. Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and dunning R3327 PAP Adenocarcinoma before and after castration
52. Expression of vascular endothelial growth factor receptors in human prostate cancer
53. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue
54. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor
55. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens
56. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo
57. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model
58. SU5416 is a potent and selective inhibitor of the vascular endothelil growth factor receptor (Flk-l/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
59. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library
60. Monoclonal antibodies targeting the VEGF receptor-2 (Flkl/KDR) as an anti-angiogenic therapeutic strategy
61. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester
62. Metalloproteinases in tumor progression: The contribution of MMP-9
63. Secretion of matrix metalloproteinases and their inhibitors (Tissue Inhibitor of Metalloproteinases) by human prostate in explant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues
64. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia
65. Location of 72-kd metalloproteinase (Type IV Collagenase) in untreated prostatic adenocarcinoma
66. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
67. Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: Implications for angiogenesis
68. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance
69. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma
70. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3
71. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
72. Human prostate tumor angiogenesis in nude mice: Metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells
73. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo
74. Plasminogen activators in human prostate cancer cell lines and tumors: Correlation with the aggressive phenotype
75. Modulation by bovine angiogenin of tubular morphogenesis and expression of plasminogen activator in bovine endothelial cells
76. Tumor cells secrete an angiogenic factor that stimulates basic fibroblast growth factor and urokinase expression in vascular endothelial cells
77. Regulation of distinct steps of angiogenesis by different angiogenic molecules
78. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells
79. Regulation of angiogenesis by extracellular matrix: The growth and the glue
80. In vivo angiogenic activity of urokinase: Role of endogenous fibroblast growth factor-2
81. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model
82. Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse
83. Antibodies to plasminogen activator inhibit human tumor metastasis
84. Antimetastatic effect of amiloride in an animal tumour model
85. Inhibition of urokinase by 4-substituted Benzo[b]thiophene-2-carboxamidines: An important new class of selective synthetic urokinase inhibitor
86. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade
87. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents
88. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents
89. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers
90. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers
91. Human prostatic cancer cells are sensitive to programmed (Apoptotic) death induced by the antiangiogenic agent linomide
92. Activation of programmed cell death in the rat ventral prostate after castration
93. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation
94. The biology of hormone refractory prostate cancer. Why does it develop?
95. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma
96. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
97. Angiostatin induces and sustains dormancy of human primary tumors in mice
98. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo
99. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin
100. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth
101. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis
102. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
103. Tumour regression after endostatin therapy
104. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
105. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding
106. Endostatin induces endothelial cell apoptosis
107. Angiogenesis inhibitor TNP-470 inhibits growth and metastasis of a hormone-independent rat prostatic carcinoma cell line
108. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines
109. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2
110. Characterization of the human kallikrein locus
111. Antiangiogenic activity of prostate-specific antigen
112. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine
113. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate